Cardiomyopathy

Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Translational Approaches to Septic Cardiomyopathy

Conditions:   Cardiomyopathies;   Sepsis;   Septic Shock
Intervention:  
Sponsors:   Samuel Brown;   Euan Ashley
Recruiting - verified August 2017

Nitrite in Hypertrophic Cardiomyopathy (HCM) Study

Condition:   Cardiomyopathy, Hypertrophic
Interventions:   Drug: Sodium Nitrate;   Drug: Placebo;   Diagnostic Test: Phosphorous Magnetic Resonance Spectroscopy;   Diagnostic Test: Exercise Stress Transthoracic Echocardiogram
Sponsors:   University of East Anglia;   Norfolk and Norwich University Hospitals NHS Foundation Trust;   British Medical Research Council
Recruiting - verified August 2017

Survey of QRS Frequency at Various Left Ventricular Pacing Sites for Cardiac Resynchronization

Conditions:   Cardiomyopathies;   Congestive Heart Failure
Intervention:   Device: Biotronik Vision Guidewire
Sponsor:   The Cleveland Clinic
Recruiting - verified August 2017

Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve

Conditions:   Hypertrophic Cardiomyopathy;   Non-ischemic Dilated Cardiomyopathy;   Microvascular Ischaemia of Myocardium
Interventions:   Drug: Regadenoson;   Drug: Adenosine
Sponsor:   Duke University
Not yet recruiting - verified August 2017

Cardiac Blood Flow Patterns Associated With Left Ventricular Myocardial Damage

Conditions:   Cardiomyopathies;   Myocardial Injury;   Healthy
Intervention:   Diagnostic Test: Single Group Assignment
Sponsors:   Medical University of Graz;   OeNB Anniversary Fund
Enrolling by invitation - verified August 2017

Amiodarone Usage After Ischemic Ventricular Tachycardia Ablation

Conditions:   Ischemic Cardiomyopathy;   Ventricular Tachycardia;   ICD Shock
Intervention:   Procedure: Ventricular tachycardia ablation
Sponsor:   Yuksek Ihtisas Hospital
Recruiting - verified August 2017

Proof-of-Concept Study of Heart Habits Application for Patients With Heart Failure

Condition:   Heart Failure
Interventions:   Behavioral: Heart Failure Education and Management App;   Behavioral: Heart Failure Literature
Sponsors:   Jana Care;   Massachusetts General Hospital
Not yet recruiting - verified August 2017

Multicenter Exploratory Study of Accelerometry in Dilated Cardiomyopathy

Condition:   Dilated Cardiomyopathy
Interventions:   Device: Cardea SOLO;   Device: ActiGraph wGT3X-BT;   Device: Wavelet Wristband
Sponsor:   Stanford University
Not yet recruiting - verified August 2017

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Condition:   Heart Failure With Preserved Ejection Fraction
Interventions:   Drug: Macitentan;   Drug: Placebo
Sponsor:   Actelion
Recruiting - verified August 2017

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

Condition:   Heart Failure
Interventions:   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Neladenoson bialanate (BAY1067197);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified August 2017

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2017

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2017

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Condition:   Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified August 2017

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

Condition:   Heart Failure
Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
Sponsors:   Amgen;   Cytokinetics;   Servier
Recruiting - verified August 2017

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Condition:   Transthyretin (TTR) Amyloid Cardiomyopathy
Intervention:   Drug: Tafamidis meglumine
Sponsor:   Pfizer
Recruiting - verified August 2017

LifeVest Wearable Cardioverter Defibrillator WEARIT-III Registry

Condition:   Ischemic Heart Failure
Intervention:   Device: LifeVest 4000
Sponsors:   Zoll Medical Corporation;   University of Rochester
Recruiting - verified August 2017

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

Conditions:   Inherited Cardiac Arrythmias;   Long QT Syndrome (LQTS);   Brugada Syndrome (BrS);   Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT);   Early Repolarization Syndrome (ERS);   Arrhythmogenic Cardiomyopathy (AC, ARVD/C);   Hypertrophic Cardiomyopathy (HCM);   Dilated Cardiomyopathy (DCM);   Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy);   Normal Control Subjects
Intervention:  
Sponsor:   Johns Hopkins University
Enrolling by invitation - verified August 2017

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

Condition:   Primary Systemic (AL) Amyloidosis
Interventions:   Drug: NEOD001;   Other: Placebo
Sponsor:   Prothena Therapeutics Ltd.
Active, not recruiting - verified August 2017

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

Condition:   BRAF V600E Mutation
Interventions:   Drug: Dabrafenib Mesylate;   Drug: Trametinib Dimethyl Sulfoxide
Sponsor:   National Human Genome Research Institute (NHGRI)
Suspended - verified July 19, 2017

MOMENTUM 3 IDE Clinical Study Protocol

Condition:   Advanced Refractory Left Ventricular Heart Failure
Interventions:   Device: HeartMate 3 LVAS;   Device: HeartMate II LVAS
Sponsors:   Thoratec Corporation;   St. Jude Medical
Active, not recruiting - verified August 2017

Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

Conditions:   Cardiomyopathy;   Coronary Artery Disease;   Congestive Heart Failure;   Myocardial Infarction
Interventions:   Device: Implantable Cardioverter Defibrillator;   Other: Optimal Medical Therapy
Sponsor:   VA Office of Research and Development
Recruiting - verified August 2017

CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients

Conditions:   Non-left Bundle Branch Block;   Ischemic or Non-ischemic Cardiomyopathy
Interventions:   Other: QLV based implant strategy;   Other: Standard of care implant strategy
Sponsor:   St. Jude Medical
Active, not recruiting - verified August 2017

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

Condition:   Heart Failure With Preserved Ejection Fraction
Interventions:   Drug: LCZ696;   Drug: Valsartan
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting - verified August 2017

IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG

Conditions:   Myocardial Infarct;   Heart Failure
Intervention:   Procedure: Injection of stem cells at time of coronary artery bypass grafting
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Miltenyi Biotec, Inc.;   Centre de Recherche du Centre Hospitalier de l'Université de Montréal;   Maisonneuve-Rosemont Hospital
Completed - verified July 2015

Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention

Conditions:   Heart Failure, Congestive;   Death, Sudden, Cardiac;   Arrhythmia;   Cardiomyopathies
Intervention:  
Sponsors:   Johns Hopkins University;   University of Maryland;   Washington Hospital Center;   Virginia Commonwealth University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2017

Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)

Conditions:   Transthyretin Mutations;   Transthyretin Amyloidosis
Intervention:   Other: None. Observational Study.
Sponsor:   Pfizer
Recruiting - verified August 2017